Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2014—OvaGene Oncology announced it has entered into a research and development collaboration with Hitachi Chemical Research Center to bring novel mRNA-based signatures to the gynecologic oncology market. The collaboration is founded on Hitachi Chemical’s patented exosome technologies and OvaGene’s research, clinical validation, and translational focus.
December 2014—Omicia, a genome interpretation company, announced the commercial availability of Opal Clinical, the company’s software-as-a-service solution for diagnostic testing organizations. With Opal Clinical, users can launch NGS tests faster and interpret results more accurately and quickly, the company said in a statement.
December 2014—Aquaro Biosystems introduced its PaceSetter section mounting system, a benchtop instrument that automates the transfer of paraffin-embedded tissue sections directly from microtomes to glass slides.
December 2014—T2 Biosystems received FDA market authorization for its T2Candida Panel and T2Dx Instrument for the direct detection of candida species in human whole blood specimens from patients with symptoms of, or medical conditions predisposing patients to, invasive fungal infections.
December 2014—Sysmex America announced an amended distributorship agreement with Laboratory Supply Co. This agreement is for Sysmex reagents, controls, and instruments, including the Sysmex XS-1000i, Sysmex pocH-100i, Sysmex XP-300, XT-Series, and XN-Series automated hematology analyzers.
December 2014—Thermo Fisher Scientific announced the successful CE-IVD registration of its Ion PGM Dx System for sale in European countries. The system was developed using the Ion Torrent next-generation sequencing technology, currently used in clinical research laboratories to produce tests to uncover meaningful genetic information for a range of human conditions.
December 2014—Roche and ARK Diagnostics announced a distribution agreement that will enable laboratories to integrate ARK’s Methotrexate test into the Roche therapeutic drug monitoring menu for its Cobas c 501 and Cobas c 502 clinical chemistry analyzers.
December 2014—Abbott’s DNA test for the detection of high-risk human papillomavirus is now available in Europe. The test identifies women at increased risk for development of cervical cancer or the presence of high-grade disease.
November 2014—Siemens Healthcare, in agreement with Inpeco, has won an exclusive contract to automate a new, 200,000-square-foot clinical laboratory of Quest Diagnostics in Marlborough, Mass. This will be the first comprehensive automation solution Quest has deployed in one of its regional mega-laboratories in the United States.
November 2014—Randox released a white paper focusing on the importance of quality control in point-of-care testing. The white paper will help laboratories define an appropriate QC procedure for all point-of-care devices.
